

Appendix 2.

RNA quantification using NanoDrop

RNA quantification using NanoDrop: Controls subjects

No.	Type	Sample	Absorbance ratio A_{260} / A_{280}	Concentration (ng/ μ l)
1	Control	CMC	1.86	46.2
2	Control	CLX	1.92	36.1
3	Control	CLQ	1.87	83.9
4	Control	CLT	1.90	82.1
5	Control	CLI	1.92	35.9
6	Control	CLR	1.82	88.2
7	Control	CLL	1.96	88.5
8	Control	CMD	1.86	54.7
9	Control	CLW	1.95	41.0
10	Control	CMB	2.14	13.6
11	Control	CMK	1.93	43.6
12	Control	CMJ	1.91	67.9
13	Control	CMG	1.90	90.4
14	Control	CMH	1.87	82.9

RNA quantification using NanoDrop: Patient subjects with single sampling

No.	Type	Sample	Absorbance ratio A_{260} / A_{280}	Concentration (ng/ μ l)
15	Patient	LE	1.85	27.6
16	Patient	LF	1.90	24.0
17	Patient	LH	1.91	21.4
18	Patient	LJ	1.90	21.4
19	Patient	LK	1.97	14.9
20	Patient	LZ	1.87	69.6
21	Patient	MA	1.86	118.7
22	Patient	MC	2.13	24.4
23	Patient	LM	1.84	83.8
24	Patient	LX	2.01	96.5
25	Patient	LD	2.02	23.4
26	Patient	LG	1.88	44.8
27	Patient	BD	1.90	47.8
28	Patient	E	1.91	35.9
29	Patient	BB	1.83	118.5
30	Patient	LC	1.90	14.6
31	Patient	LQ	1.95	82.8
32	Patient	MD	1.94	66.8
33	Patient	LV	1.91	93.5
34	Patient	LI	2.09	25.2
35	Patient	ME	2.01	60.2

RNA quantification using NanoDrop: Patient subjects with subsequent sampling

No.	Type	Sample	Absorbance ratio A_{260} / A_{280}	Concentration (ng/ μ l)
36	Patient	LS ₁	1.97	14.28
		LS ₂	1.94	23.9
37	Patient	MB ₁	1.86	57.7
		MB ₂	1.85	66.8
38	Patient	LR ₁	1.92	82.5
		LR ₂	1.85	50.2
39	Patient	LA ₁	1.81	10.3
		LA ₂	1.94	13.9
40	Patient	LB ₁	2.09	29.9
		LB ₂	2.02	22.8
41	Patient	LT ₁	1.80	68.0
		LT ₂	2.03	22.5
42	Patient	BE ₁	1.94	29.4
		BE ₂	1.99	23.3
43	Patient	LN ₁	1.84	88.6
		LN ₂	1.86	120.0
44	Patient	LY ₁	1.87	87.8
		LY ₂	1.84	48.5
45	Patient	DB ₁	1.92	38.4
		DB ₂	1.94	71.1
46	Patient	LL ₁	1.81	48.6
		LL ₂	1.92	48.0